The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Maxeon Solar Technologies said it is establishing an alternative network of supply-chain partners and increasing its manufacturing capabilities in the U.S. as it deals with new tariffs and trade ...

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) gapped down before the market opened on Wednesday after an insider sold shares in the company. The stock had previously closed at ...

Shares of Eli Lilly, the seller of Zepbound, were down 2.7% to $718.50 after the close on Friday. Novo Nordisk, the maker of Wegovy, saw its stock decline 1.4% to $61.67. Shares of Hims & Hers, a ...

BTIG analyst David Larsen maintained a Buy rating on Simulations Plus (SLP – Research Report) today and set a price target of $41.00. The ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Edgewise Therapeutics (EWTX – Research Report), ...

The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.

Thermo Fisher Scientific TMO has unveiled its latest customer-centric innovation, the Thermo Scientific Krios 5 Cryo-Transmission Electron Microscope (TEM). The next-generation atomic-resolution ...

Extending coverage for the medications through Medicare could cost $35 billion over nine years, a congressional analysis ...

As the U.S. stock market grapples with volatility driven by escalating trade tensions and significant index declines, investors are increasingly seeking stability amid uncertainty. In this climate, ...

In the wake of recent market turbulence sparked by new tariffs, U.S. indices have experienced significant declines, highlighting the volatility and uncertainty that currently characterize the ...

One way to get an idea of the market sentiment on a stock is to check its rate of institutional ownership. In the case of ...